Insider Activity and Regulatory Milestones for Guardant Health Amid Stock Volatility
John G. Saia, Chief Legal Officer at Guardant Health, Inc., recently sold a significant block of common stock. This transaction occurs against a backdrop of positive regulatory news, including early FDA approval for the G360 Liquid CDx test, alongside more recent mixed financial results for the company in Q1 2026.